Bioventus (BVS)
NASDAQ:BVS
Top Page
Bioventus
(NASDAQ:BVS)
Select Model
Select Model
Rating:65Neutral
Price Target:
$10.00
▲(13.12% Upside)
Action:ReiteratedDate:03/06/26
The score is driven primarily by improving financial performance (profitability rebound and strong free cash flow) and supportive technical momentum (price above key moving averages). Offsetting factors are a still-risky balance sheet history/leverage sensitivity and only moderate valuation support (P/E ~21.8 with no dividend), while earnings call guidance and deleveraging targets provide a constructive but not risk-free outlook given near-term headwinds.
Positive Factors
Cash generation
Sustained high operating and free cash flow provides durable internal funding for R&D, product commercialization, and debt reduction. Free cash flow roughly tracking net income and record quarterly cash from operations improve financial flexibility and reduce reliance on external financing over the medium term.
Negative Factors
Historical leverage
A recent history of high leverage constrains financial flexibility and raises interest-expense sensitivity to rate moves. While debt levels have declined and management targets further deleveraging, lingering leverage increases vulnerability to operational setbacks and limits capital allocation options if cash flow weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Sustained high operating and free cash flow provides durable internal funding for R&D, product commercialization, and debt reduction. Free cash flow roughly tracking net income and record quarterly cash from operations improve financial flexibility and reduce reliance on external financing over the medium term.
Read all positive factors
Bioventus (BVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$760.03M
Dividend YieldN/A
Average Volume (3M)257.41K
Price to Earnings (P/E)8.4
Beta (1Y)0.88
Revenue Growth1.58%
EPS GrowthN/A
CountryUS
Employees930
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.24
Shares Outstanding67,368,050
10 Day Avg. Volume219,442
30 Day Avg. Volume257,406
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.69
Price to Sales (P/S)0.87
P/FCF Ratio6.94
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit2.26
Enterprise Value/Ebitda8.30
Forecast
1Y Price Target
$14.75Price Target Upside66.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.75
Revenue Forecast (FY)$604.27M
Bioventus Business Overview & Revenue Model
Company Description
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pa...
How the Company Makes Money
Bioventus generates revenue through multiple streams, primarily from the sale of its medical devices, biologic products, and therapeutic solutions. The company has a strong focus on the orthopedic market, where it markets its ultrasound devices an...
Bioventus Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Data provided by:
The Fly
The FlyBioventus Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call conveyed strong underlying progress: accelerating organic growth (10% Q4), substantial margin expansion, record quarterly cash from operations and successful pilot validation for PNS and PRP with a committed incremental investment plan. Management also communicated concrete deleveraging progress and clear 2026 guidance. Near-term headwinds include FX impacts, distributor/timing effects that contributed to Q4 and are expected to pressure Q1, a headline revenue increase that is modest (+3%) versus organic growth, and a Q4 Restorative Therapies decline driven by a divestiture. Overall, the positive operational and financial momentum, successful pilots and disciplined capital allocation outweigh the transitory challenges highlighted for the early part of 2026.Positive Updates
Quarterly Revenue and Organic Growth
Q4 revenue of $158 million, a 3% increase year-over-year, with 10% organic growth after adjusting for the Advanced Rehabilitation divestiture; management highlighted a year-over-year acceleration in the second half of 2025 driven by Pain Treatments and Restorative Therapies.
Negative Updates
Headline Revenue Growth Moderation
Headline Q4 revenue grew only 3% YoY ($158 million), which is materially lower than the 10% organic rate—indicating volatility and notable one-time/adjustment effects in the quarter.
Read all updates
Q4-2025 Updates
Positive
Negative
Quarterly Revenue and Organic Growth
Q4 revenue of $158 million, a 3% increase year-over-year, with 10% organic growth after adjusting for the Advanced Rehabilitation divestiture; management highlighted a year-over-year acceleration in the second half of 2025 driven by Pain Treatments and Restorative Therapies.
Read all positive updates
Company Guidance
Bioventus guided 2026 net sales of $600–$610 million, adjusted EPS of $0.73–$0.77, and cash from operations of $82–$87 million (a ~10–17% increase), targeting an adjusted EBITDA margin of approximately 20% for the year while expecting adjusted earnings growth to outpace revenue growth; the company plans roughly $13 million of incremental investment behind PNS, PRP, ultrasonics and international (PNS+PRP expected to contribute at least 200 basis points of growth in 2026 with further acceleration in 2027), expects to reduce net leverage from below 2.5x to well under 2x by year‑end, notes Q1 will be the weakest quarter (impacted by one fewer selling day and HA distributor inventory rebalancing) with revenue and adjusted EBITDA highest in Q4, and says the guidance assumes no additional U.S. dollar fluctuation.Bioventus Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
45
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 568.09M | 573.28M | 512.35M | 512.12M | 430.90M |
| Gross Profit | 382.43M | 388.23M | 328.19M | 331.08M | 302.71M |
| EBITDA | 105.56M | 39.22M | -23.07M | -121.61M | 45.48M |
| Net Income | 22.73M | -33.54M | -156.23M | -158.70M | 19.38M |
Balance Sheet | |||||
| Total Assets | 683.56M | 727.96M | 810.91M | 1.37B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 51.24M | 41.58M | 36.96M | 30.19M | 43.93M |
| Total Debt | 311.35M | 335.63M | 394.85M | 418.07M | 357.68M |
| Total Liabilities | 455.11M | 542.35M | 589.79M | 960.43M | 692.07M |
| Stockholders Equity | 184.10M | 147.94M | 173.59M | 325.24M | 458.92M |
Cash Flow | |||||
| Free Cash Flow | 71.41M | 37.79M | 7.98M | -15.02M | 2.10M |
| Operating Cash Flow | 73.98M | 38.80M | 15.34M | -13.54M | 22.99M |
| Investing Cash Flow | -3.25M | 22.96M | 15.81M | -116.44M | -283.76M |
| Financing Cash Flow | -61.44M | -54.58M | -26.65M | 62.08M | 273.37M |
Bioventus Technical Analysis
Neutral
8.84
Price Trends
8.61
Positive
8.07
Positive
7.49
Positive
Market Momentum
0.11
Positive
49.50
Neutral
40.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Neutral. The current price of 8.84 is below the 20-day moving average (MA) of 8.95, above the 50-day MA of 8.61, and above the 200-day MA of 7.49, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 49.50 is Neutral, neither overbought nor oversold. The STOCH value of 40.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BVS.
Bioventus Risk Analysis
Bioventus disclosed 80 risk factors in its most recent earnings report. Bioventus reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioventus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $760.03M | 8.40 | 4.97% | ― | 1.58% | ― | |
56 Neutral | $615.22M | -45.38 | -12.91% | ― | 23.27% | 43.90% | |
55 Neutral | $404.71M | -10.51 | -12.67% | ― | 19.90% | -57.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $489.76M | -6.56 | -20.38% | ― | 4.31% | 3.26% | |
46 Neutral | $462.58M | 52.93 | -13.86% | ― | 4.14% | -45.29% |
* Healthcare Sector Average
BVS
Bioventus
9.14
1.19
14.97%
OFIX
Orthofix Medical
12.20
-2.52
-17.12%
VREX
Varex Imaging
11.04
2.35
27.04%
KIDS
OrthoPediatrics
16.01
-7.02
-30.48%
SIBN
SI-Bone
13.93
<0.01
0.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.